Compounds > methyl 5-(n-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate
Page last updated: 2024-11-12

methyl 5-(n-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methyl 5-(N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate: a malonyl-CoA decarboxylase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10206413
CHEMBL ID206562
SCHEMBL ID6843689
MeSH IDM0497323

Synonyms (6)

Synonym
CHEMBL206562 ,
bdbm50183332
methyl 5-(n-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)morpholine-4-carboxamido)pentanoate
5-{(morpholine-4-carbonyl)-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethylethyl)phenyl]amino}pentanoic acid methyl ester
SCHEMBL6843689
dktuevoktcnlnr-uhfffaoysa-n
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Malonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)IC50 (µMol)0.04190.04170.04190.0420AID261285; AID311036
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
response to ischemiaMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
acetyl-CoA biosynthetic processMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
fatty acid biosynthetic processMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
acyl-CoA metabolic processMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
response to nutrientMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
regulation of glucose metabolic processMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
fatty acid oxidationMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
regulation of fatty acid beta-oxidationMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
positive regulation of fatty acid oxidationMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
malonyl-CoA catabolic processMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
identical protein bindingMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
malonyl-CoA decarboxylase activityMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
mitochondrionMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
mitochondrial matrixMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
peroxisomeMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
peroxisomal matrixMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
cytosolMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
peroxisomal matrixMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
mitochondrial matrixMalonyl-CoA decarboxylase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID261293Increase in glucose oxidation rate in ischemic pig heart2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID261287Solubility in PBS at pH 7.42006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID261288Caco-2 cell membrane permeability2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID311036Inhibition of human recombinant MCD2007Bioorganic & medicinal chemistry, Jul-01, Volume: 15, Issue:13
3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
AID261290Stability in human liver microsomes at 5 uM2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID261291Glucose oxidation rate in isolated working hearts of Sprague-Dawley rat at 20 uM relative to DMSO2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID261294Decrease in lactate production in ischemic pig heart2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID261285Inhibition of MCD2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
AID261289Stability in rat liver microsomes at 5 uM2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship of small-molecule malonyl coenzyme A decarboxylase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
trimetazidine
Trimetazidine: A vasodilator used in angina of effort or ischemic heart disease.		2.0310aromatic amine
ranolazine
Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.		2.0310aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol
malonyl coenzyme a
Malonyl Coenzyme A: A coenzyme A derivative which plays a key role in the fatty acid synthesis in the cytoplasmic and microsomal systems.. omega-carboxyacyl-CoA : An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of any alpha,omega-dicarboxylic acid.		2.4920malonyl-CoAsEC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor;
Escherichia coli metabolite;
metabolite;
mouse metabolite
bafilomycin a1
bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.		2.3110cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
ConditionIndicatedRelationship StrengthStudiesTrials
Heart Disease, Ischemic
[description not available]		02.0310
Myocardial Ischemia
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).		02.0310
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		02.3110
Impaired Glucose Tolerance
[description not available]		02.1310
Insulin Sensitivity
[description not available]		02.520
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.1310
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.520
Glucose Intolerance
A pathological state in which BLOOD GLUCOSE level is less than approximately 140 mg/100 ml of PLASMA at fasting, and above approximately 200 mg/100 ml plasma at 30-, 60-, or 90-minute during a GLUCOSE TOLERANCE TEST. This condition is seen frequently in DIABETES MELLITUS, but also occurs with other diseases and MALNUTRITION.		02.1310